However, a recent large multicentral cohort within the Asian Breast Cancer Cooperative Group (n = 28,280), reported a better relapse-free survival rate in HER2-low BCs, rather than in HER2-negative BCs in their multivariable analysis14. Here, ERBB2 is linked to breast cancer.